Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Zhong Nanshan: It is suggested to use heterologous vaccines for sequential vaccination. New report v-01
Published Time：
2022-06-13
Zhong Nanshan suggests using heterologous vaccines for sequential vaccination (Photo by Xia Yan, CNR reporter)
Guangzhou, June 11 (CNR reporter Xia Yan) - On June 10, the 14th China Bioindustry Convention High-Level Forum opened in Guangzhou. Zhong Nanshan, an academician of the Chinese Academy of Engineering, delivered a keynote speech entitled "Technological Fight Against the Epidemic - Preventing the Epidemic, Stabilizing the Economy." He suggested using heterologous vaccines for sequential vaccination.
Zhong Nanshan introduced that using the same type of vaccine for booster shots has a poor effect in preventing COVID-19 infection; however, using heterologous vaccines for booster shots, such as adding subunit protein vaccines, adenovirus vaccines, or mRNA vaccines after two doses of inactivated vaccines, significantly improves the effect. Based on the dynamic zero-COVID policy (not only reducing the severity rate and mortality rate, but also reducing the infection rate), Zhong Nanshan suggested using heterologous vaccines for sequential vaccination.
Zhong Nanshan pointed out that currently, all COVID-19 vaccines on the market, including four doses of mRNA vaccines, are not enough to effectively prevent Omicron infection. "One month after four doses of mRNA vaccination, the effective rate of preventing Omicron infection is 11% (Moderna vaccine) or 30% (Pfizer vaccine), and the viral load of breakthrough infections is high, and the infectivity is strong."
Zhong Nanshan pointed out that the absolute protective efficacy of V-01 sequential booster (against Omicron) is comparable to that of mRNA vaccine booster immunization (Photo by Xia Yan, CNR reporter)
"Based on two doses of inactivated vaccines, the absolute protective efficacy of V-01 sequential booster (against Omicron) is comparable to that of mRNA vaccine booster immunization." Zhong Nanshan said.
It is reported that the results of randomized double-blind phase III clinical trials in Pakistan and Malaysia show that sequential booster shots based on two doses of inactivated vaccines can achieve 61.35% absolute protection against Omicron infection, 71.83% absolute protection for patients with underlying diseases, and 61.19% absolute protection for patients over 60 years old or with underlying diseases.
In addition, Zhong Nanshan also introduced newly developed vaccines in China, including subunit protein vaccines, second-generation mRNA vaccines, and inhaled (nebulized, nasal spray) vaccines. "Domestic second-generation mRNA sequential vaccines can significantly improve neutralization against the Omicron variant." Zhong Nanshan said.
This article is transferred from: CNR
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.